Researchers with the University of Colorado clinically investigated Longvida's ability to improve vascular endothelial function, as assessed by endothelium dependent dilation (EDD), in middle-aged and older adults. After 12 weeks of 2000mg per day of Longvida® Optimized Curcumin, brachial artery flow-mediated dilation (FMDba) was increased by 36% versus placebo, which showed no change. Results, published in January 2017, indicate that Longvida improves vascular endothelial function by increasing nitric oxide bioavailability through a reduction in oxidative stress and inflammatory signaling in middle-aged and older adults. According to the authors, these results support evidence that supplementation of Longvida may be a promising therapeutic option to improve vascular health. Further, this clinical provides additional support for Longvida’s efficacious ability to promote healthy aging.
These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
Please note that the physiological activity of the ingredient(s) described herein is supported by the referenced clinical trial reports. Marketers of finished products containing the ingredient(s) described herein are responsible for determining whether claims made for such products are lawful and in compliance with the laws of the country in which they will market the products.
For our most current patent information, please visit: www.vs-corp.com/ip
© Copyright | All Rights Reserved Careers | Intellectual Property | Terms Conditions